Edition:
United States

Coherus BioSciences Inc (CHRS.OQ)

CHRS.OQ on NASDAQ Stock Exchange Global Market

11.11USD
17 Jan 2019
Change (% chg)

-- (--)
Prev Close
$11.11
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
237,097
52-wk High
$20.65
52-wk Low
$8.34

Latest Key Developments (Source: Significant Developments)

Coherus BioSciences Announces Prime Vendor Program Contract Agreement With Apexus
Friday, 30 Nov 2018 09:30am EST 

Nov 30 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES ANNOUNCES APEXUS CONTRACT AGREEMENT FOR 340B HOSPITALS AND CLINICS, AND Q-CODE ISSUANCE FROM CMS.COHERUS BIOSCIENCES INC - HAS RECEIVED Q-CODE MEDICAL BILLING STATUS FOR UDENYCA FROM CENTERS FOR MEDICARE AND MEDICAID SERVICES.  Full Article

Coherus Biosciences Q3 Loss Per Share $0.87
Thursday, 8 Nov 2018 04:01pm EST 

Coherus BioSciences Inc ::COHERUS BIOSCIENCES REPORTS CORPORATE HIGHLIGHTS AND THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.87.Q3 EARNINGS PER SHARE VIEW $-0.77 -- THOMSON REUTERS I/B/E/S.CASH AND CASH EQUIVALENTS AND INVESTMENTS IN MARKETABLE SECURITIES TOTALED $117.2 MILLION AS OF SEPTEMBER 30, 2018.  Full Article

Coherus BioSciences Says FDA Approves UDENYCA (pegfilgrastim-cbqv)
Friday, 2 Nov 2018 01:40pm EDT 

Nov 2 (Reuters) - Coherus BioSciences Inc ::U.S. FDA APPROVES UDENYCA™ (PEGFILGRASTIM-CBQV).COHERUS BIOSCIENCES INC - UDENYCA™ (PEGFILGRASTIM-CBQV) APPROVED BY BOTH FDA & EUROPEAN COMMISSION.  Full Article

Coherus Biosciences Says ‍Had Cash And Cash Equivalents Of About $126.9 Million
Friday, 5 Jan 2018 04:08pm EST 

Jan 5 (Reuters) - Coherus Biosciences Inc ::COHERUS BIOSCIENCES SAYS ‍HAD CASH AND CASH EQUIVALENTS OF ABOUT $126.9 MILLION AS OF DEC 31 - SEC FILING​.  Full Article

Coherus Says Judge Issued Under Seal Report & Recommendation In Relation To Patent Infringement Complaint
Friday, 8 Dec 2017 01:11pm EST 

Dec 8 (Reuters) - Coherus Biosciences :COHERUS SAYS U.S. JUDGE RECOMMENDED COURT GRANT CO'S PENDING MOTION TO DISMISS AMGEN'S COMPLAINT FOR FAILURE TO STATE CLAIM .COHERUS BIOSCIENCES SAYS ON DEC 7, JUDGE ISSUED UNDER SEAL REPORT AND RECOMMENDATION TO DISTRICT COURT IN RELATION TO PATENT INFRINGEMENT COMPLAINT.COHERUS BIOSCIENCES SAYS CO EXPECTS DISTRICT COURT TO DECIDE IN Q1 2018 WHETHER TO ADOPT MAGISTRATE JUDGE'S RECOMMENDATION - SEC FILING.COHERUS BIOSCIENCES SAYS ‍REPORT AND RECOMMENDATION ISSUED BY JUDGE WITH RESPECT TO LITIGATION BETWEEN AMGEN, AMGEN MANUFACTURING LTD, CO​.  Full Article

Coherus Biosciences Q3 loss per share $1.09
Monday, 6 Nov 2017 04:00pm EST 

Nov 6 (Reuters) - Coherus Biosciences Inc :Coherus Biosciences reports third quarter 2017 operating and financial results.Q3 loss per share $1.09.Q3 earnings per share view $-0.81 -- Thomson Reuters I/B/E/S.Coherus biosciences inc - ‍anticipate cash use in operations of about $35 - $40 million in Q4 of 2017​.  Full Article

Coherus Biosciences files for offering of upto 6.56 million shares of common stock by the selling stockholder‍​
Friday, 22 Sep 2017 05:35pm EDT 

Sept 22 (Reuters) - Coherus Biosciences Inc :Coherus Biosciences Inc - Files for offering of upto 6.56 million shares of common stock by the selling stockholder‍​ - SEC filing.  Full Article

Coherus Biosciences says ‍PTAB denied 4 petitions for inter partes review of Abbvie's patent
Thursday, 7 Sep 2017 11:57am EDT 

Sept 7 (Reuters) - Coherus Biosciences Inc :Coherus Biosciences provides update on ‘619 IPR institution decision.Says ‍PTAB denied institution of all 4 petitions for inter partes review of Abbvie's patent related to Abbvie's Humira formulation​.  Full Article

Coherus Biosciences announces positive topline results for study for Humira biosimilar vs European marketed Humira in healthy subjects
Monday, 28 Aug 2017 08:30am EDT 

Aug 28 (Reuters) - Coherus Biosciences Inc :Coherus Biosciences announces positive topline results for clinical pharmacokinetic bioequivalence study for CHS-1420 (Humira® biosimilar candidate) versus European marketed Humira in healthy subjects.Coherus Biosciences Inc - ‍Study met criteria for clinical PK/BE on all prospectively defined endpoints​.Coherus Biosciences - ‍Both agents well tolerated, there were no clinical meaningful differential adverse events observed between two agents in study​.  Full Article

Coherus secures private placement from Temasek
Monday, 21 Aug 2017 08:30am EDT 

Aug 21 (Reuters) - Coherus Biosciences Inc :Coherus secures private placement from Temasek.Coherus Biosciences Inc - ‍Temasek plans to invest up to $150 million over two tranches​.Coherus Biosciences Inc - ‍First tranche of $75 million in gross proceeds to be completed and funded by August 31, 2017 with 6.6 million shares of common stock​.Coherus Biosciences Inc - ‍Second tranche is projected to be funded following receipt of U.S. FDA marketing approval for CHS-1701​.Coherus Biosciences - Intends to use net proceeds from private placements for capital for completion of development and registration of CHS-1701.  Full Article

Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount

Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount.